TradingKey

关于 Repligen Corp 公司

Repligen Corporation 是一家全球生命科学公司，致力于开发和商业化生物加工技术和系统。其重点领域是过滤和流体管理、色谱、过程分析和蛋白质。其过滤产品用于工艺开发和工艺规模（临床和商业）生产。其 XCell ATF 系统用于上游灌注（连续）和 N-1（强化补料分批或混合灌注）细胞培养处理。其色谱特许经营包括用于生物药物下游纯化、开发、制造和质量控制的多种产品。其过程分析产品补充并支持其过滤、色谱和蛋白质特许经营。其 TangenX 产品组合包括主要用于下游和超滤过程的平板 (FS) 切向流过滤 (TFF) 盒。其桌面产品组合包括 MAVERICK 和 MAVEN、REBEL 和 ZipChip。

公司简介

公司代码RGEN

公司名称Repligen Corp

上市日期Apr 29, 1986

CEOMr. Olivier Loeillot

员工数量1778

证券类型Ordinary Share

年结日Apr 29

公司地址Building 1, Suite 100

城市WALTHAM

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02453

电话17814499560

网址https://www.repligen.com/

公司代码RGEN

上市日期Apr 29, 1986

CEOMr. Olivier Loeillot

公司高管

名称

名称/职务

职务

持股

持股变动

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

14.31K

-14.90%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

--

Mr. Jason K. Garland

Chief Financial Officer

--

Mr. Tony John Hunt

Executive Chairman of the Board

--

Dr. Martin D. Madaus, Ph.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

14.31K

-14.90%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

暂无数据

地区USD

名称

营收

占比

North America

84.59M

50.00%

Europe

59.21M

35.00%

APAC/Other

25.38M

15.00%

业务

地区

暂无数据

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

其他

67.25%

持股股东

占比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

其他

67.25%

股东类型

持股股东

占比

Investment Advisor

59.57%

Investment Advisor/Hedge Fund

25.36%

Hedge Fund

13.00%

Individual Investor

6.39%

Research Firm

2.39%

Pension Fund

2.37%

Bank and Trust

0.68%

Sovereign Wealth Fund

0.59%

Family Office

0.50%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

2023Q2

1050

59.01M

105.99%

+1.34M

2023Q1

1061

58.23M

104.67%

+1.01M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

5.07M

9.02%

-21.20K

-0.42%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.89M

8.7%

+13.96K

+0.29%

Mar 31, 2025

T. Rowe Price Associates, Inc.

7.52M

13.38%

+427.74K

+6.03%

Mar 31, 2025

Roy T. Eddleman UEO

3.31M

5.89%

-67.50K

-2.00%

Dec 31, 2024

Point72 Asset Management, L.P.

1.12M

1.99%

+197.82K

+21.53%

Mar 31, 2025

State Street Global Advisors (US)

1.69M

3.01%

-2.27K

-0.13%

Mar 31, 2025

Champlain Investment Partners, LLC

1.46M

2.61%

-79.53K

-5.15%

Mar 31, 2025

Sands Capital Management, LLC

1.29M

2.3%

-70.06K

-5.14%

Mar 31, 2025

Invesco Advisers, Inc.

1.60M

2.84%

+768.85K

+93.02%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Alger Mid Cap 40 ETF

4.16%

First Trust NYSE Arca Biotechnology Index Fund

3.18%

Invesco Biotechnology & Genome ETF

2.7%

BNY Mellon Innovators ETF

2.6%

iShares Health Innovation Active ETF

1.64%

VanEck Biotech ETF

1.39%

Franklin Genomic Advancements ETF

1.24%

Congress SMid Growth ETF

1.24%

WisdomTree BioRevolution Fund

1%

Pacer US Export Leaders ETF

0.93%

Alger Mid Cap 40 ETF

占比4.16%

First Trust NYSE Arca Biotechnology Index Fund

占比3.18%

Invesco Biotechnology & Genome ETF

占比2.7%

BNY Mellon Innovators ETF

占比2.6%

iShares Health Innovation Active ETF

占比1.64%

VanEck Biotech ETF

占比1.39%

Franklin Genomic Advancements ETF

占比1.24%

Congress SMid Growth ETF

占比1.24%

WisdomTree BioRevolution Fund

占比1%

Pacer US Export Leaders ETF

占比0.93%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Repligen Corp

121.658USD

Repligen Corp

121.658

概览

公司

财务

分析